Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
Company Growth (employees)
Type
Public
HQ
Boston, US
Founded
1989
Size (employees)
2,150 (est)
Website
vrtx.com
Vertex Pharmaceuticals was founded in 1989 and is headquartered in Boston, US

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has an office in Boston
Boston, US (HQ)
50 Northern Ave

Vertex Pharmaceuticals Data and Metrics

Vertex Pharmaceuticals Financial Metrics

Vertex Pharmaceuticals's revenue was reported to be $714.7 m in Q1, 2017
USD

Revenue (Q1, 2017)

714.7 m

Net income (Q1, 2017)

249.5 m

EBIT (Q1, 2017)

270.8 m

Market capitalization (17-Aug-2017)

37.4 b

Cash (31-Mar-2017)

1 b
Vertex Pharmaceuticals's current market capitalization is $37.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.2 b580.4 m1 b1.7 b

Revenue growth, %

(52%)78%65%

R&D expense

1 b

Operating expense total

2.1 b1.3 b1.5 b1.7 b

EBIT

(903.4 m)(692.4 m)(466.9 m)9.9 m

EBIT margin, %

(75%)(119%)(45%)1%

Interest expense

22.7 m72.9 m84.2 m81.4 m

Interest income

22.7 m

Pre tax profit

(976.1 m)

Income tax expense

(288.6 m)7 m30.4 m16.7 m

Net Income

(687.6 m)(742.7 m)(588.2 m)(84 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

138.4 m179 m138.5 m166.1 m309.8 m398.1 m431.6 m413.8 m714.7 m

R&D expense

224.8 m190.9 m215.6 m223.9 m246.3 m255.9 m271 m272.4 m273.6 m

Operating expense total

224.8 m190.9 m215.6 m223.9 m246.3 m255.9 m271 m272.4 m273.6 m

EBIT

(180.8 m)(142.2 m)(172 m)(171.2 m)(70 m)(14.3 m)3.4 m(18.7 m)270.8 m

EBIT margin, %

(131%)(79%)(124%)(103%)(23%)(4%)1%(5%)38%

Interest expense

(15.6 m)(20.4 m)(21.3 m)(21.1 m)(21.1 m)(20.7 m)(20.2 m)(20.1 m)(16.8 m)

Pre tax profit

(18 m)(39 m)

Income tax expense

693 k3.4 m299 k30.1 m1.3 m5.5 m18.1 m503 k4 m

Net Income

(159.4 m)(198.7 m)(221 m)(93.8 m)(36.1 m)(36.2 m)(39.5 m)249.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

569.3 m625.3 m714.8 m1.2 b

Accounts Receivable

85.5 m76 m177.6 m201.1 m

Inventories

14.1 m30.8 m57.2 m77.6 m

Current Assets

1.6 b1.5 b1.4 b1.8 b

PP&E

696.9 m715.8 m697.7 m698.4 m

Goodwill

31 m39.9 m50.4 m50.4 m

Total Assets

2.3 b2.3 b2.5 b2.9 b

Accounts Payable

49.3 m71.2 m74.9 m61.5 m

Current Liabilities

397.8 m368.3 m506.3 m792.5 m

Total Liabilities

1.6 b

Additional Paid-in Capital

5.3 b5.8 b6.2 b6.5 b

Retained Earnings

(4 b)(4.7 b)(5.3 b)(5.4 b)

Total Equity

1.1 b1.3 b

Financial Leverage

2.3 x2.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

420.6 m718.6 m664.9 m870.5 m756.3 m604.2 m605.9 m719.7 m1 b

Accounts Receivable

81.8 m114.3 m80.3 m94.5 m165.3 m181.9 m189.4 m182.2 m208 m

Inventories

12 m16.8 m34.1 m42.1 m49.2 m63.2 m66.6 m71.8 m82 m

Current Assets

1.3 b1.7 b1.4 b1.3 b1.4 b1.4 b1.5 b1.5 b1.9 b

PP&E

730 m720.9 m708.6 m713.4 m706.7 m690.5 m690.6 m687.6 m708.4 m

Goodwill

31 m31 m39.9 m50.4 m50.4 m50.4 m50.4 m50.4 m50.4 m

Total Assets

2.1 b2.4 b2.2 b2.4 b2.4 b2.5 b2.5 b2.6 b2.9 b

Accounts Payable

55.4 m38.5 m43.5 m72.7 m78.9 m75.2 m51.3 m50.9 m63.1 m

Current Liabilities

363 m372.2 m302.4 m373.8 m375 m552 m622.9 m722.8 m489.8 m

Additional Paid-in Capital

5.5 b5.7 b5.9 b6 b6.1 b6.3 b6.4 b6.4 b6.6 b

Retained Earnings

(4.4 b)(4.5 b)(4.9 b)(5.1 b)(5.2 b)(5.3 b)(5.4 b)(5.4 b)(5.1 b)

Total Equity

1 b1.1 b1.1 b1.2 b1.2 b1.7 b

Financial Leverage

2.3 x2.3 x2.2 x2.2 x2.2 x1.8 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(687.6 m)(742.7 m)(588.2 m)(84 m)

Depreciation and Amortization

48.4 m63.3 m62.3 m61.4 m

Accounts Receivable

53.4 m7.4 m(100 m)(33 m)

Inventories

7.1 m(16 m)(23 m)(16.5 m)

Accounts Payable

(49.2 m)25 m(1.7 m)(11.7 m)

Cash From Operating Activities

(51.6 m)(513.2 m)(365.4 m)

Cash From Investing Activities

(54.1 m)74 m268.9 m104.5 m

Cash From Financing Activities

180.9 m497.4 m188.9 m133.3 m

Interest Paid

11 m8.7 m85.6 m83.7 m

Income Taxes Paid

2.8 m1.2 m1.8 m
USDQ2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(159.4 m)(198.7 m)(221 m)(93.8 m)(36.1 m)(36.2 m)(39.5 m)249.5 m

Accounts Receivable

94.5 m165.3 m181.9 m189.4 m182.2 m208 m

Inventories

42.1 m49.2 m63.2 m66.6 m71.8 m82 m

Accounts Payable

72.7 m78.9 m75.2 m51.3 m50.9 m63.1 m
USDY, 2017

Revenue/Employee

332.4 k

Financial Leverage

1.8 x

Vertex Pharmaceuticals Market Value History

Traffic Overview of Vertex Pharmaceuticals

Vertex Pharmaceuticals Online and Social Media Presence

Vertex Pharmaceuticals Company Life and Culture

You may also be interested in